Business Wire

The Estée Lauder Companies Strengthens Its Global Fulfillment Network with the Opening of a New, State-of-the-Art Galgenen Distribution Center Dedicated to the Travel Retail Channel

7.6.2022 16:00:00 EEST | Business Wire | Press release

Share

The Estée Lauder Companies (ELC) today announced the opening of its new, state-of-the-art distribution center located in Galgenen, Switzerland to accommodate the dynamic and future growth of its global Travel Retail business. Travel Retail, which covers the world of duty-free environments including airports, downtown locations, airlines, cruises and border shops, is one of the company’s highest growth channels and touches over 3 billion consumers a year. This new 300,000 square foot facility expands upon the company’s existing distribution footprint in Switzerland and will enable ELC to remain at the forefront of delivering its prestige beauty products and high-touch services to traveling consumers around the world. The center is equipped to support the continued growth of Travel Retail and will further drive the company's sustainability efforts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005792/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Umair Ansari, VP/GM, Travel Retail EMA, Fabrizio Freda, President and Chief Executive Officer, Jane Lauder, EVP, Enterprise Marketing and Chief Data Officer, and Roberto Canevari, EVP, Global Supply Chain cut the ribbon at the new Galgenen distribution center. (Photo: Business Wire)

Fabrizio Freda, President and Chief Executive Officer, Israel Assa, Global President, Travel Retail Worldwide and Roberto Canevari, Executive Vice President, Global Supply Chain hosted the opening ceremony with Nadine Graf, Senior Vice President, General Manager, Europe, Middle East, and Africa (EMEA), Maike Kiessling, General Manager, Switzerland, Jamal Chamariq, Senior Vice President, Global Supply Chain, EMEA and Travel Retail Worldwide and Sascha Trabelsi, Vice President, Supply Chain, Travel Retail Worldwide. The opening ceremony was attended by special guests including retailers, suppliers, local government officials, media and ELC employees.

“Travel Retail continues to demonstrate its resilience, driving tremendous growth over the last decade for The Estée Lauder Companies. We remain extremely confident in the channel for the long-term, especially as travel restrictions ease globally and people start traveling again,” said Fabrizio Freda. “The opening of our new Galgenen distribution center will enable us to adapt even better to ever-changing retail needs and growth opportunities for the channel, and expand upon our existing distribution presence in Switzerland.”

The Estée Lauder Companies’ Travel Retail division is the market share leader in the channel within the total beauty category across skin care, makeup, fragrance and hair care1. With a strong brand portfolio that resonates with consumers globally, ELC’s Travel Retail division continually demonstrates best-in-class marketing activations tailored to travelers’ needs, recruits new consumers and builds brand equity around the world. Accounting for 28% of ELC’s sales in fiscal year 2021, Travel Retail is uniquely positioned to win in this high growth environment with the company’s recent investment to expand its distribution network to meet the demands of the traveling consumer population.

“As we mark the 30th anniversary of The Estée Lauder Companies’ Travel Retail business, we are incredibly proud of our track record of exciting and delighting travelers all over the world with our exclusive products and high-touch experiences for the Travel Retail industry and having made the channel an integral engine of growth for ELC,” said Israel Assa. “As we look to the future, this investment here at Galgenen is a testament to our belief in the long-term growth potential of this channel and that by investing in these capabilities and with our retailers, we can capture the next generation of growth in this dynamic, prestige marketplace.”

The Estée Lauder Companies has a long history of success within Switzerland, opening its affiliate office more than 55 years ago and its first manufacturing plant more than 45 years ago. As the fifth largest employer in the canton of Schwyz, ELC prides itself on its inclusive and collaborative culture, competitive compensation and benefits, career development opportunities, commitments to health, safety and sustainability, and high-performance. The company currently has four distribution centers in Switzerland. Switzerland is also home to ELC’s EMEA and TR Supply Chain Management Hub in Wollerau, which drives agility, speed, and collaboration across our EMEA and Travel Retail supply chain teams. With the addition of the new facility in Galgenen, the Travel Retail business will double its total output capacity, enabling the flexibility necessary to adapt to the channel’s high growth potential.

“Galgenen will serve as a cornerstone of The Estée Lauder Companies’ agile, global fulfillment network,” said Roberto Canevari. “This distribution center will not only significantly enhance our capacity but enable operational efficiencies, speed-to-market and resiliency through innovative, highly automated equipment and technologies. Additionally, we are proud that Galgenen is also a shining example of ELC’s commitment to safety, quality, and sustainability.”

Galgenen will further advance the sustainability of ELC’s global manufacturing and distribution network and the company through its best-in-class environmental design and renewable energy efforts. The building’s design is based on the newest standards to reduce energy and water consumption. It features total LED lighting, an energy-efficient HVAC system and the roof’s solar panels generate 1600 kilowatts at peak performance (kWp). Furthering sustainability efforts, a comprehensive waste management system has been implemented to separate out numerous recyclables, with electric trucks ready for waste removal. As part of the recycling undertaking, wooden waste pallets will generate renewable heating energy. Worldwide, ELC is driving strategic initiatives to reduce its environmental footprint, integrate environmentally responsible practices and invest in innovative technology as part of efforts to not only provide consumers with transformative products and experiences, but also to contribute to the well-being of the planet.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced and Dr. Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

[1] Generation Research 2020

ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Colleen T. Leahy
cleahy@estee.com

Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye